Bell Textron signed a teaming agreement with Sierra Nevada…

Bell Adds SNC to Team Invictus for Work on Advanced Mission Systems

March 08, 2022 09:00 AM Eastern Standard Time
ORLANDO, Fla. & AUSTIN, Texas--( BUSINESS WIRE )--DeCurtis Corporation (“DeCurtis” or the Company”), a provider of location and proximity-based software to the travel and hospitality industries, today announced the receipt of a substantial strategic investment from Invictus Global Management, LLC (together with its affiliates, “Invictus”). DeCurtis provides software solutions across the cruise line, theme park, hospitality, restaurant and related industries where high-quality technology is critical to sustainable growth. The DeCurtis Experience Platform (DXP) is an end-to-end, enterprise grade software solution that enables location and proximity-based services to assist in operational efficiency, experience enhancement and customer engagement. The investment and relationship with Invictus will provide working capital to allow the Company to focus on strategic initiatives as the travel and hospitality sectors re-emerge from the pandemic. Invictus joins Shamrock Capital Advisors, LLC (“Shamrock Capital”), a Los Angeles-based investment firm, as a strategic partner to DeCurtis. Shamrock Capital previously announced a strategic growth investment in the Company in May 2019. Derek Fournier, President and CEO of DeCurtis, commented:
“We are excited to announce this partnership with Invictus. This investment will enable us to continue to grow and scale our business to further penetrate the hospitality and travel verticals. We look forward to continuing to work closely with Invictus to optimize our core business and provide additional value to our customers.”
Andy Schwalb, Chief Technology Officer of Virgin Voyages, added:
“We are excited about the announcement around Invictus and DeCurtis. DeCurtis has been a valuable partner and knowing they have secured additional financial strength will allow even more growth and investment in their platform. This in turn will enable us to continue improving on what we feel is the most advanced experience platform at sea and further enhance the Sailor journey through technology.”
Cindy Chen Delano, Founder of Invictus Global Management, commented:
“Invictus is proud to be a working capital provider and strategic partner to DeCurtis alongside of Shamrock Capital. We are impressed with the innovative technology the DeCurtis team has built and are eager to work with the Company to unlock additional value. We see tremendous growth potential and opportunities to increase operational efficiency and provide a seamless customer experience through its innovative platform.”
Andy Howard, Partner at Shamrock Capital, added:
“Shamrock Capital welcomes Invictus as a fellow strategic partner to DeCurtis. We believe the additional capital from Invictus will help the Company make significant progress towards its larger vision and ultimate growth aspirations. We view this investment as transformational for the business and look forward to having Invictus’ expertise and support.”
About DeCurtis Corporation
DeCurtis Corporation is the premier provider of location and proximity enabled solutions in complex indoor environments with a focus on health, safety and security, operational enhancement and experience evolution. Creator of Mobile Assembly Suite (MAS™), the DeCurtis Experience Platform '(DXP™), and DeCurtis Shield™, DeCurtis Corporation is the leader in providing transformational experience technology based on decades of deep industry knowledge in the cruise space that is applicable to other sectors. With a vast range of experience working with some of the world’s best, most-recognized brands, DeCurtis Corporation transforms the guest experience to be safer, secure and more efficient through the creative application of the latest technology. For more information on DeCurtis Corporation, please visit www.decurtis.com . About Invictus Global Management
Invictus Global Management is an SEC-registered investment firm based in Austin, Texas. The firm was founded by Amit Patel and Cindy Chen Delano to invest in special situations with particular emphasis on private debt solutions in complex litigation-oriented situations. The firm has a flexible mandate, and its investments typically exhibit minimal correlation to global financial markets. Invictus believes its ability to deliver long-term value for investors is a result of its transparent and open culture that promotes and nurtures high-performing talent with diverse perspectives, experiences and strong ethical values. About Shamrock Capital
Shamrock Capital is a Los Angeles-based investment firm with approximately $3.9 billion of assets under management. Shamrock Capital invests exclusively in media, entertainment, communications, and related sectors through a multi-fund strategy centered on private equity investments and entertainment intellectual property rights ownership. The firm was originally founded in 1978 as the family investment company for the late Roy E. Disney and has since evolved into an institutionally backed firm with a leading group of investors, including endowments, foundations, and sovereign wealth and pension funds. Shamrock Capital partners with strong management teams and takes an active, collaborative approach to creating value in each investment. For more information, visit Shamrockcap.com . Contacts

DeCurtis Corporation Announces Strategic Investment from Invictus Global Management

Team Aster OGA Season 6 China betting picks
February 24, 2022
News Snapshot:
With the Dota Pro Circuit’s regional finals now done, third-party events are filling the gap. The best one going on at the moment is OGA Dota PIT Season 6, which is hosting matches between big names from the region including Team Aster and Invictus Gaming. The event has been bringing together top Chinese teams throughout, and the action isn’t being dialed down in the playoffs. After taking upper bracket losses, Team Aster and Invictus Gaming will be fighting for their lives in the lower bracket. How did they get to this point and how have these teams been performing of...

Invictus Gaming vs. Team Aster OGA Season 6 China betting picks

China News, Data, Media Intelligence and Insights
Search for:
Source:
February 19, 2022
05:07
20:26
02:57
14:10
fiorreports.com
© 2022 ChinaPulse.com. Individual news stories are copyright their respective sources. Computer algorithms generally select what is shown on ChinaPulse.com. The algorithms determine which stories, images, and videos show, and in what order. Posting....

02/08
02/13/2022 | 05:12pm EST
Message :
Address: Level 45, MLC Centre, 19 Martin Place, Sydney NSW 2000
www.vgiht.com | Tel: +61 2 8279 8908
VGI Health Technology executes Term Sheet for sale
of the Invictus BioPharma Group
Sydney, New South Wales, 14 February 2022 - VGI Health Technology Limited (NSX:VTL or Company) is pleased to announce that it has executed a non-binding Term Sheet for the sale of its wholly- owned subsidiary, the Invictus BioPharma Pty Ltd Group (Invictus Group) to Invictus BioPharma Holdings Ltd (IVBHL). IVBHL is a company founded by VTL's CEO and Managing Director, Dr Glenn Tong, VTL's Chief Scientific Officer and Chair of its Scientific Advisory Board, Dr David Kingston and VTL's wholly-owned US subsidiary, Invictus Nutraceuticals Inc's, President and CEO Mr Richard Estalella. The Term Sheet prescribes an Exclusivity Period which extends for three months after the date of execution of the Term Sheet or the execution of a Share Purchase Agreement (SPA), whichever is the earlier. During this Exclusivity Period, VTL will not directly or indirectly negotiate, plan, solicit, initiate or respond to any other proposal or offer to acquire all or a substantial part of the Invictus Group. The Key Terms that have been agreed in principle by VTL and IVBHL are as follows:
A cash payment of $2,300,000 by IVBHL to VTL
Issue of shares in the capital of IVBHL equating to no less than 20% of the total capital on issue in IVBHL (following any seed round capital raise dilution). These shares are to be issued to VTL on completion of the transaction. VTL is to be granted a first right of refusal / pre-emption in relation to any future capital raisings undertaken by IVBHL on a pro rata basis. As an illustrative example, if the VTL owns 20% of the IVBHL, and IVBHL conducts a capital raising for $2,000,000, the right of first refusal/pre- emption will apply to a $400,000 investment by VTL. VTL agrees to hand over the Invictus Group free of financial indebtedness on completion of this transaction. The Invictus Group includes Invictus Biotechnology Pty Ltd. which owns the patent rights to the "Transmucosal Delivery of Tocotrienols" patent estates and also the licensed patent rights from Monash University for tocotrienol prodrugs. IVBHL will transfer the ownership of the US subsidiary, Invictus Nutraceuticals, Inc., to VTL for nil consideration. IVBHL is to grant VTL an exclusive perpetual global licence to manufacture, market and sell nutraceutical products based on the Invictus Group's intellectual property rights, with a royalty payable of 10% of net profit after tax. IVBHL is to grant VTL an exclusive perpetual licence to manufacture, market and sell pharmaceutical products based on the Invictus Group's intellectual property rights in the
Peoples Republic of China with a royalty payable of 10% of net profit after tax. 1
VGI Health Technology Limited
The completion of the sale and purchase of the Invictus Group to IVBHL is subject to, and conditional upon, VTL obtaining all required shareholder approvals to the transaction pursuant to the Corporations Act (Cth) 2001 (Corporations Act) and the NSX Listing Rules (including, but not limited to, approval under Chapter 2E of the Corporations Act, including the requirement to procure an Independent Expert's Report, and NSX Listing Rules 6.41 and 6.43). Anticipated Timing for the Transaction
The anticipated timing for this transaction is as follows:
Execute SPA - 25 February 2022
Complete NOM/IER - 18 March 2022
ASIC review period of NOM/IER ends - 1 April 2022
Issue NOM/IER to Shareholders of VTL - 5 April 2022
EGM - 3 May 2022
Completion - 10 May 2022
Upon completion of this transaction, VTL will focus on the manufacturing, marketing and sale of nutraceutical products which are both proprietary and patent protected, an example being NE1- Elite® and NE1-Heart®, both of which are available through Amazon.com in the US and listed as Listed Medicines on Australia's Therapeutic Goods Administrations' Australian Register of Therapeutic Goods. Upcoming Board and Management Changes
VTL Changes
Upon completion of this transaction, Drs Tong and Kingston will resign from their present roles in VTL and existing Director Mr Steven Yu will be appointed Managing Director. The Company is in discussions to appoint a new Director reflecting a more revenue generating focussed business of VTL post completion. Mr Estalella will act as an advisor to VTL in relation to the commercialisation of nutraceutical products, particularly in the US (including Canada and South America), Japan and the EU. IVBHL Changes
Drs Tong and Kingston will take up the roles of Executive Chairman and CEO in the case of Dr Tong and Chief Medical Officer and Chair of the Scientific Advisory Board in the case of Dr Kingston for IVBHL. At the same time, Mr Estalella will resign from his present role in Invictus Nutraceuticals, Inc. and be appointed an Executive Director and the Vice President of Corporate Affairs for IVBHL. IVBHL
Upon completion of the proposed transaction, IVBHL will be a clinical-phase drug development company which will focus on the development of drugs based on the transmucosal delivery of tocotrienols and tocotrienol prodrugs. Two drug candidates based on the transmucosal delivery of tocotrienols, IVB001 targeting Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic Steatohepatitis (NASH) and IVB003 targeting Pancreatic Adenocarcinoma (Pancreatic Cancer) are presently commencing Phase II clinical studies. Two tocotrienol prodrug candidates, IVB002 and IVB004, are presently being optimised in a continuing collaborative research project with Professor Christopher Porter's research group at the Monash Institute of Pharmaceutical Sciences
2
VGI Health Technology Limited
(MIPS) and is expected to commence formal preclinical studies in H2 of 2022 in preparation for clinical studies in 2023. The Rationale for the Proposed Transaction
The directors of VTL, through their capital raising efforts for the Company to date, have received a clear message from investors that VTL's combination of both a human consumer health business and a drug development business is difficult for most investors to understand. There are investors who understand and are interested in investing in a human consumer health business which has the potential to generate imminent revenues from product sales and there are other investors who understand and are interested in investing in a drug development business which has the potential to generate massive growth in company value through achievement of clinical development and corporate transaction milestones. However, it is seldom that both these groups of investors intersect. Further, the drug development business is more suitable for listing on a stock exchange which caters better for capital-intensive, high growth companies in the biotechnology sector. Therefore, the directors see the proposed transaction as beneficial to VTL as it allows the Company to focus all of its resources on the commercialisation of nutraceutical products globally and to target the appropriate investor base for this type of business. At the same time, the equity stake which VTL has in IVBHL through this transaction will allow VTL's shareholders to share in any value generated by IVBHL should the drug development activities bear fruit without the need for VTL to invest heavily in IVBHL's drug development program. For more information please contact:
Glenn Tong, CEO and Managing
Catriona Glover, Company
About VGI Health Technology Limited
VGI Health Technology Limited trading as VGI Health Technology is an Australian public listed biotechnology company (NSX:VTL) developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. VTL owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines. For more information see: https://www.vgiht.com
Investors interested in trading shares on the NSX should contact a broker who is an NSX Participant: https://www.nsx.com.au/broker_list_print.asp
3

VGI Health Technology : executes Term Sheet for sale of the Invictus BioPharma Group

Alphatec is an audio distributor of loudspeakers, amplifiers, mixers, powered mixers, computer-based recording, DJ products, microphones, headphones, musical instruments, wireless systems, and MIDI controllers. It is based in Mumbai, India.

Alphatec

`` The InVictus system is an important addition to our comprehensive posterior solution as it opens the door for surgeons to increasingly partner with ATEC for MIS degenerative and deformity applications .

ATEC Extends InVictus MIS Platform With Commercial Release Of InVictus MIS Tower - Tullis Funds

CannAmerica Brands (CSE:CANA) (CNSX:CANA.CN) (OTC:CNNXF) is a cannabis branding, licensing and intellectual property company with a portfolio of premium cannabis brands in the United States.

CannAmerica Brands

Workwear Group offers a brand and product portfolio comprising leading brands with over 85 years of experience.

Workwear Group

Westpac Group's portfolio of financial services brands and businesses is focused on providing quality services to businesses and individuals. With a strategic focus on Australia, New Zealand and the near Pacific, the Westpac Group provides a broad range of banking and financial services – including retail, business and institutional banking.

Westpac Group

Crossfit is a gym that provides accredited training seminars throughout the world.On June 25th, 2020, Crossfit was acquired by Eric Roza. The terms of the transaction were not disclosed.

Crossfit

Nextwin, dba Invictus, provides an artificial intelligence platform that predicts the outcome of sporting events. Invictus aims to help users improve their bets with a combination of machine learning and expert intelligence.

Date	9/6/2018
Round	Debt
Amount	$25.5M
Investors	ATB Financial
Valuation
Revenue	0 FY undefined
Sources	1

Wells Fargo Success Story

3M Success Story

Platform Overview

Invictus

Total Raised

Invictus Funding, Invictus Valuation & Invictus Revenue

Discover the right solution for your team